2. Academic Validation
  3. Linezolid is superior to vancomycin in experimental pneumonia caused by Superantigen-Producing staphylococcus aureus in HLA class II transgenic mice

Linezolid is superior to vancomycin in experimental pneumonia caused by Superantigen-Producing staphylococcus aureus in HLA class II transgenic mice

  • Antimicrob Agents Chemother. 2012 Oct;56(10):5401-5. doi: 10.1128/AAC.01080-12.
Melissa J Karau 1,  Ashenafi Y Tilahun,  Suzannah M Schmidt,  Chad R Clark,  Robin Patel,  Govindarajan Rajagopalan
Affiliations

Affiliation

  • 1 Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
PMID: 22850509 DOI: 10.1128/AAC.01080-12
Abstract

Superantigens (SAg), the potent activators of the immune system, are important determinants of Staphylococcus aureus virulence and pathogenicity. Superior response to SAg in human leukocyte antigen (HLA)-DR3 transgenic mice rendered them more susceptible than C57BL/6 mice to pneumonia caused by SAg-producing strains of S. aureus. Linezolid, a Bacterial protein synthesis inhibitor, was superior to vancomycin in inhibiting SAg production by S. aureus in vitro and conferred greater protection from pneumonia caused by SAg-producing staphylococci.

Figures
Products